Kader is invited as speaker to the 5th Annual Conference in Vienna.

1. visit our website:
www.jacobfleming.com
5th Annual Licensing in Generics
Bringing together licensors and licenses
to maximize profitability of all parties involved
11th & 12th May 2010, Vienna
v
Our Expert Advisors Find your reasons to attend
v
Rahul Garella, Glenmark Generics, UK How successful are you in grasping key opportunities to give/take a license and
SVP EU Business expand into attractive markets? How to optimize a business development strategy
in times, when payers and patients are looking to save money wherever possible?
Matevz Kmet, Teva, Slovenia Leading generics players understand, how to establish and maintain partnerships,
Strategic Planning and Head Licensing-In that will strengthen their position in key markets. Reveal, how to make licensing
and partnering a key strategy to achieve a profitable growth. Utilize the market
Elif Celik, Zentiva, Turkey opportunities for biosimilars, understand what are top selling products and
General Manager expected expiry dates. Leading generics companies will share their first hand
experience, how they tackle pricing, regulatory and IP challenges to ensure success
Corinne Zucco, Zentiva, France of their business development strategy.
Head In-Licensing This event will bring together business development executives and senior experts
from the generics industry presenting real life case studies as well as a lot of
Martin Spatz, Ratiopharm, Austria
networking sessions and breaks specially designed for business discussions.
Head Portfolio Management Join us, meet new business partners & explore future partnering opportunities.
Juan Luis Fernandez Balaguer, Zydus Group, Spain Critical insights into evolving trends in licensing & partnering - new
General Manager business models for partnering in Europe & globally
Understand the pricing & regulatory scenario for generics in UK
with Winthrop (Sanofi Aventis)
YOUR PRESTIGIOUS SPEAKER PANEL Explore with Veropharm the business strategy of Russian
manufacturers in generic portfolio development – learn about the
government programs and healthcare reforms in Russia
Rahul Garella, Glenmark Generics, UK Reveal the major generics market developments with Manuel Plaza
Senior Vice President EU Business – forming the future of strategic business development for the
generics industry
Harvinder Popli, Ranbaxy, India
Exploit the market opportunities for biosimilars in emerging markets
Head In-Licensing with Ranbaxy – real life case studies from the Indian experience
Manuel Plaza, Teva Spain Listen to the Egis case study on utilizing the licensing and partnership
Former CEO potential in dynamic CEE markets
Optimizing business development strategy in a highly competitive
Fadi Nassar, Hikma, Jordan and crowded markets
Corporate Vice President API Managing Intellectual Property challenges
James Amihood, Perrigo, Israel And much more…
Vice President Business Development
Kit Britten, Winthrop (Sanofi Aventis), UK PLUS SPECIAL FEATURE!
Vice President Commercial Development
Be a part of Business Networking Sessions!
Matthias Heidt, Abdi Ibrahim, Turkey
Take the opportunity to meet your business partners, collect new
Business Development Director business contacts and talk face to face in a series of business meetings
Ilya Nilva, Veropharm, Russia
Marketing & Portfolio Director v
Kader Comlekci, Zentiva, Turkey Who MUST attend
Head R&D Formulation
CEOs, Managing Directors, Chief Licensing Officers, Vice Presidents, Senior
Mariusz Strutynski, Egis, Poland Executives, Heads, Directors and Managers of: Business Development and
Business Development Manager Licensing, Licensing, Technology Licensing, Patent Licensing, Product Licensing &
Development, Licensing & External Research, Regulatory Affairs, Strategic Planning,
Mourad Ishak, Sandoz, Egypt Corporate Development, Commercial Development, API, Sourcing API, Intellectual
Marketing Manager Property, Patent Attorneys, Supply & Logistics Operations, Contract Management

2. Booking line: tel: + 421 257 272 149, fax: + 421 257 272 277
DAY 1, May 11th , 2010 14:10 CASE STUDY How do we maximize the potential
of licensing - how to strengthen the position
8:30 Registration and coffee in key markets & achieve the competitive
advantage
• Optimizing resource utilization for global business
9:00 Opening remarks from the chair
development activities
• Designing and implementing new in-/out-licensing
Grasping the full potential of biosimilars strategy – key steps
• Benchmarking licensing models we have in place –
major learnings
9:10 KEYNOTE PRESENTATION Current trends and market
James Amihood, Perrigo
opportunities in emerging markets in biosimilars: Vice President Business Development
case studies from the Indian experience
• Overview of market
14:50 CASE STUDY Revealing the licensing opportunities
- Overall market Assessment
- Emerging markets in dynamic CEE markets
• Key potential Opportunities • In-licensing & out-licensing experience from the CEE
- Biological classes region
- Top selling products, expected expiry etc. • How to cope with major obstacles in the region –
• Current trends and regulatory reforms in India Hungary, Poland, Czech Republic, Russia and Ukraine
• Building Blocks of a Successful Bio segment • Competing in a crowded generics market through
• Exploring New Avenues licensing
• Real life case studies of success Mariusz Strutynski, Egis
Harvinder Popli, Ranbaxy Business Development Manager
Head In-Licensing
15:30 Afternoon tea & networking
Critical insights into evolving trends in
Meet & collect new business contacts
licensing & partnering in Europe & globally
9:50 Recent market developments and the impact 16:30 CASE STUDY The real situation in Russia 2010
on business development and licensing activities – new business models for generics
• Key trends forming the future of generics industry • Government programs in Healthcare & pharmaceutical
• Shifting focus in selecting markets, partners and industry modernization
products – examples • Results & forecast for a Russian generics market
• Ciritical thoughts on launching new generics into the • Business strategy of Russian manufacturers in generic
market portfolio development – Veropharm examples
• Major trends in in-licensing and out-licensing – grasping • Company units participation in business procedures
the opportunities where they are • Niche strategy
• Common pitfalls of license agreements – key learnings • Export Opportunities
Manuel Plaza, Teva Spain Ilya Nilva, Veropharm
Former CEO Marketing & Portfolio Director
10:30 Interactive Q & A session 17:10 CASE STUDY Unexploited opportunities
Featuring speakers from the morning session in Licensing
• Pharmaceutical industry growth by strategic activity
10:50 Morning coffee and networking • Licensing as a life cycle management tool
• Illness in licensing
• Licensing and unexploited brands
• Licensing and limited exposure brands
11:20 Business Networking Session
• Attractive markets for licensing
Meet new business contacts Mourad Ishak, Sandoz
Talk face to face in a series of business meetings Head of Marketing
Choose & attend the networking session dedicated to
your main area of interest, there will be 2 main groups
created: 17:50 Interactive Q & A session
1. In-Licensing Featuring speakers from the afternoon session
2. Out-Licensing
18:10 Close of Day 1
12:30 Luncheon
Speakers and delegates are cordially invited to attend a
Networking Cocktail Reception

3. email: genericslicensing@jacobfleming.com, www.jacobfleming.com
DAY 2, May 12th, 2010 14:10 CASE STUDY Key success factors for developing
business in a changing environment of Turkey
8:30 Registration and Coffee • Common business practices & trends in a „formerly“
emerging maket
• Current changing rules in Turkey with dramatic price
9:00 Opening remarks from the chair
cuts & protectionism – impact on business development
• Growing in volume as well as valuewise – what’s the
Optimizing business development strategy reality?
in a new reality • How to tackle the increased pressure on pricing in an
optimal way – first hand experience
Matthias Heidt, Abdi Ibrahim
9:10 Current pricing
KEYNOTE PRESENTATION Business Development Director
& regulatory scenario for generics in UK
• General situation for licensed products & partnering in a
14:50 CASE STUDY API sourcing challenges
generics UK market
• Essential pricing & regulatory considerations for • Leveraging the attractiveness of different alternatives to
generics source attractive APIs
• New policy measures for the generic industry to prevent • Optimizing the sourcing strategy
ruinous price decay – impact on business development • Hurdles and weak points in partnering wtih API suppliers
and value of license agreements – major learnings
• Launching new generics – accelerating time to market Fadi Nassar, Hikma
• Examples Corporate Vice President API
Kit Britten, Winthrop (Sanofi Aventis)
Vice President Commercial Development 15:30 Afternoon tea & networking
Meet & collect new business contacts
9:50 CASE STUDY Recent evolution of partnering
models across major European markets
16:30 CASE STUDY Technical, development
• Mid-term vs long-term perspective on partnership and and commercial evaluation of business
licensing models in Europe development opportunities
• Exploring the specifics of giving the license to a specific • Most promising areas for generic drug development -
market (country- & product-wise) – potential difficulties, selection of projects/generic products at Zentiva
exploring the current trends in major generics European
• Driving API selection trough close cooperation with
markets
R&D
• Legal & IP law environment – recent patent issues for
• Key development concerns and processes to ensure
generics in Europe and the impact on our business
competitive generics pipeline for grasping strategic
model
business development opportunities
• The future of profitable and well-working partnering
• Feasibility study and risk management - approaches to
Rahul Garella, Glenmark Generics handle risks of licensed, or co-developed generics
Senior Vice President EU Business
• Preparing technical dossier for successful submission -
common pitfalls and tips
10:30 Interactive Q & A session Kader Comlekci, Zentiva
Head R&D Formulation
Featuring speakers from the morning session
10:50 Morning coffee and networking 17:10 Interactive Q & A session
Featuring speakers from the afternoon session
11:20 Business Networking Session
17:30 Closing remarks from the chair
Meet new business contacts
Talk face to face in a series of business meetings
17:40 Farewell Coffee and Networking
Choose & attend the networking session dedicated to
your main area of interest, there will be 2 main groups I would like to thank everyone who has helped with
created: the research and organization of this event, especially
3. In-Licensing the speakers and advisors for their support and
4. Out-Licensing commitment.
Dasa Laslopova, Senior Conference Producer
12:30 Luncheon dasa.laslopova@jacobfleming.com